Henry Schein reported second-quarter 2026 results with total net sales of $3.458 billion and GAAP diluted EPS of $0.82, compared with $0.70 in Q2 2025. Non-GAAP diluted EPS was $1.27 versus $1.10 a year earlier, and Adjusted EBITDA for the quarter rose to $288 million. The company raised its FY2026 guidance to non-GAAP diluted EPS of $5.29 to $5.39, with expected sales growth of 4.5%–5.5% and mid- to high-single-digit Adjusted EBITDA growth.
Financial Highlights
- Total net sales: $3,458 million for Q2 2026 (up 6.7% vs Q2 2025).
- Gross profit: $1,101 million for Q2 2026 (gross profit reported in condensed statements).
- Operating income: $171 million for Q2 2026 (as reported in condensed statements of income).
- GAAP net income attributable to Henry Schein: $94 million for Q2 2026; GAAP diluted EPS $0.82.
- Non-GAAP net income attributable to Henry Schein: $145 million for Q2 2026; non-GAAP diluted EPS $1.27. Adjusted EBITDA: $288 million for Q2 2026.
Business Highlights
- Internal (constant currency) sales growth for Q2 2026 was 4.6%, with acquisitions contributing 0.7% and foreign exchange 1.4% to total sales growth.
- Global Distribution and Value-Added Services sales increased 6.6% (4.5% internal growth); Global Dental merchandise sales rose 9.7% (5.9% internal growth).
- Global Technology sales increased 8.2%, reflecting 9.1% internal growth offset by a 1.3% decrease from a business disposal.
- Global Specialty Products sales increased 8.7%, reflecting contributions from internal growth, acquisitions and foreign exchange.
- Share repurchase activity: ~2.6 million shares repurchased in Q2 2026 for $200 million; year-to-date repurchases approximately 4.2 million shares for $325 million, with $455 million remaining authorization at quarter end.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.